Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + sibutramine
- Development stage
- Phase 3
- Lead developer
- Laboratorios Silanes
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination medication containing metformin and sibutramine used for weight management in obese patients, particularly those with type 2 diabetes. Metformin improves insulin sensitivity and reduces hepatic glucose production, while sibutramine acts as an appetite suppressant by inhibiting the reuptake of norepinephrine and serotonin.
- Brand names
- Reduxin®Met
- Other names
- sibutramine-metforminsibutramine and metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on metformin + sibutramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + sibutramine.